XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm Study
Launched by ABBOTT MEDICAL DEVICES · Mar 6, 2008
Trial Information
Current as of May 23, 2025
Completed
Keywords
ClinConnect Summary
Long term surveillance studies using a drug eluting stent (DES) may help elucidate mechanisms responsible for death, myocardial infarction, and late stent thrombosis risks not observed during controlled pre-market trials. This study will evaluate XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) performance in the "real world" when used by a broad group of physicians at a variety of health care facilities. Consequently, this protocol will include all consecutively enrolled patients in India who consent to participate and receive the XIENCE V® EECSS, which is expected to represent t...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The patient agrees to participate in this study by signing the EC approved informed consent form. Alternatively, the patient's legally authorized representative agrees to the patient's participation in this study and signs the informed consent form.
- Exclusion Criteria:
- • The inability to obtain an informed consent is an exclusion criterion.
About Abbott Medical Devices
Abbott Medical Devices is a leading global healthcare company dedicated to advancing medical technology through innovative research and development. With a robust portfolio of diagnostic, therapeutic, and monitoring solutions, Abbott is committed to improving patient outcomes and enhancing the quality of care across various medical fields. The company places a strong emphasis on clinical trials to validate the safety and efficacy of its products, ensuring compliance with regulatory standards and fostering collaboration with healthcare professionals. By leveraging cutting-edge science and technology, Abbott Medical Devices aims to address pressing health challenges and deliver transformative solutions that empower patients and healthcare providers alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Delhi, , India
Hyderabaad, Andhra Pradesh, India
Hyderabad, , India
Hyderabad, Andhra Pradesh, India
Ahmedabad, Gujarat, India
Ludhiana, Punjab, India
Vellore, Tamilnadu, India
Ahmedabad, , India
Amritsar, , India
Chennai, , India
Cochin, , India
Jaipur, , India
Mumbai, , India
New Delhi, , India
New Delhi, , India
Pune, , India
Pune, , India
Patients applied
Trial Officials
Ashok Seth, MD
Principal Investigator
Max Devki Devi Heart & Vascular Institute
Tejas Patel, MD
Principal Investigator
Krishna Heart Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials